Cantitate/Preț
Produs

Evaluation of Enzyme Inhibitors in Drug Discovery – A Guide for Medicinal Chemists and Pharmacologists, Second Edition

Autor RA Copeland
en Limba Engleză Hardback – 15 apr 2013
With enzymes being the most valued and common of drug targets, an understanding of their interactions with inhibitors is critical to successful drug discovery. Now in a second edition, this proven work clearly explains the biochemical data and experimental details underlying the science, arming medicinal chemists and pharmacologists with the tools they need to master the art of applied enzymology for drug discovery. With updated material throughout, two new chapters, and five new appendices, Evaluation of Enzyme Inhibitors in Drug Discovery, Second Edition remains the only book available on the topic.
Citește tot Restrânge

Preț: 89599 lei

Preț vechi: 94314 lei
-5% Nou

Puncte Express: 1344

Preț estimativ în valută:
17152 18685$ 14389£

Carte tipărită la comandă

Livrare economică 18 decembrie 24 - 01 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781118488133
ISBN-10: 111848813X
Pagini: 576
Dimensiuni: 163 x 245 x 38 mm
Greutate: 0.95 kg
Ediția:2nd Edition
Editura: Wiley
Locul publicării:Hoboken, United States

Public țintă

Researchers and graduate students in biotechnology, Pharmaceutical sciences, medicinal chemists and biochemists, enzymologists, bioorganic chemists, and biophysicists

Cuprins


Notă biografică

ROBERT A. COPELAND, PhD, is Executive Vice President and Chief Scientific Officer at Epizyme, Inc., a biopharmaceutical company in Cambridge, Massachusetts. He is on the Editorial Board of The Journal of Biological Chemistry and a member of the Faculty of 1000. Dr. Copeland has contributed more than 175 publications to the scientific literature and holds eight U.S.-issued patents. He has authored several books in protein science and enzymology, including Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, Second Edition (Wiley).

Descriere

With enzymes being the most valued and common of drug targets, an understanding of their interactions with inhibitors is critical to successful drug discovery.